Logo

Predicant Biosciences Obtains $7.5M Debt Financing to Develop Protein Biomarker Technology

Oct 11, 2005

NEW YORK, Oct. 11 (GenomeWeb News) - Predicant Biosciences has received $7.5 million in debt financing from Hercules Technology Growth Capital, the Palo Alto-based specialty finance company said today.

 

Predicant will use the financing to develop and market protein biomarker technology for diagnostic tests.

 

The company, based in South San Francisco, Calif., has been developing separation, detection, and informatics technologies for identifying and assaying protein biomarkers for use in diagnostics and drug development.

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.